Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review
Mechanisms Review moderate
AI-extracted · unverified · confirm at source
Comprehensive pharmacology review: noribogaine 10× more potent at SERT (IC₅₀ 0.04 vs 0.59 μM), full μ-opioid agonist (IC₅₀ 0.16 vs 11.0 μM); CYP2D6 polymorphism yields 9× lower noribogaine Cmax in PMs
Contraindications: CYP2D6 poor metaboliser status (altered ibogaine/noribogaine ratio), Pre-existing cardiac conditions (dose-dependent cardiotoxicity in preclinical models), Concomitant hepatically-metabolised drugs (CYP2D6 pathway)